The Non-Coding Regulatory Variant rs2863002 at chr11p11.2 Increases Neuroblastoma Risk by Affecting HSD17B12...

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Neuroblastoma is a common childhood cancer.
• Genome-wide association studies (GWAS) have identified genetic loci associated with neuroblastoma risk.
• The functional mechanisms underlying these associations are often unclear.

Purpose of the Study:

• To identify and functionally characterize a neuroblastoma predisposition locus at chr11p11.2.
• To investigate the role of the candidate causal variant rs2863002 in neuroblastoma development.
• To elucidate the regulatory mechanisms and biological consequences of the risk allele.

Main Methods:

• Genome-wide association study (GWAS) in a European-American cohort.
• Luciferase reporter assays to confirm cis-regulatory activity.
• Validation in an Italian case-control cohort.
• Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR), Hi-C, and CRISPR genome editing.
• In vitro functional assays and targeted lipidomic analyses.

Main Results:

• The chr11p11.2 locus was identified as a neuroblastoma predisposition locus.
• rs2863002 was implicated as the candidate causal variant with validated genetic association.
• The rs2863002-C risk allele was shown to regulate HSD17B12 expression and decrease GATA3 binding.
• This regulation impacts neuroblastoma cell tumorigenicity and lipid metabolism.

Conclusions:

• The study identifies rs2863002 at chr11p11.2 as a functional neuroblastoma risk variant.
• HSD17B12 regulation by the risk allele contributes to neuroblastoma tumorigenicity and altered lipid metabolism.
• Post-GWAS functional characterization is crucial for understanding complex disease genetics.